Last reviewed · How we verify
Depo-Medrol Injectable Product
Depo-Medrol Injectable Product, marketed by University Health Network in Toronto, is a well-established corticosteroid therapy with a strong presence in the market. The key composition patent is set to expire in 2028, providing a significant period of exclusivity and potential revenue protection. However, the lack of a clear primary indication and key trial results poses a risk in maintaining its competitive edge against emerging therapies.
At a glance
| Generic name | Depo-Medrol Injectable Product |
|---|---|
| Also known as | Methylprednisone |
| Sponsor | University Health Network, Toronto |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Post-operative Methylprednisolone Taper Course for Orthopedic Surgery (PHASE4)
- Lumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression (PHASE3)
- Particulate vs. Non-Particulate Steroid for Sacroiliac Joint Injection (PHASE4)
- Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial (PHASE2)
- The Use of Intra-articular Corticosteroid Injection to Treat Osteoarthritis of the Carpometacarpal Joint (PHASE4)
- A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain (PHASE3)
- Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis (PHASE4)
- High Volume Injection in Mid Portion AChilles Tendinopathy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Depo-Medrol Injectable Product CI brief — competitive landscape report
- Depo-Medrol Injectable Product updates RSS · CI watch RSS
- University Health Network, Toronto portfolio CI